- Research article
- Open Access
- Open Peer Review
In vitrocorrection of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique
© Sangiuolo et al; licensee BioMed Central Ltd. 2002
- Received: 29 April 2002
- Accepted: 23 September 2002
- Published: 23 September 2002
SFHR (small fragment homologous replacement)-mediated targeting is a process that has been used to correct specific mutations in mammalian cells. This process involves both chemical and cellular factors that are not yet defined. To evaluate potential of this technique for gene therapy it is necessary to characterize gene transfer efficacy in terms of the transfection vehicle, the genetic target, and the cellular processing of the DNA and DNA-vehicle complex.
In this study, small fragments of genomic cystic fibrosis (CF) transmembrane conductance regulator (CFTR) DNA, that comprise the wild-type and ΔF508 sequences, were transfected into immortalized CF and normal airway epithelial cells, respectively. Homologous replacement was evaluated using PCR and sequence-based analyses of cellular DNA and RNA. Individual stages of cationic lipid-facilitated SFHR in cultured cell lines were also examined using transmission electron microscopy (TEM).
We demonstrated that the lipid/DNA (+/-) ratio influences the mode of entry into the cell and therefore affects the efficacy of SFHR-mediated gene targeting. Lipid/DNA complexes with more negative ratios entered the cell via a plasma membrane fusion pathway. Transfer of the DNA that relies on an endocytic pathway appeared more effective at mediating SFHR. In addition, it was also clear that there is a correlation between the specific cell line transfected and the optimal lipid/DNA ratio.
These studies provide new insights into factors that underlie SFHR-mediated gene targeting efficacy and into the parameters that can be modulated for its optimization.
- gene therapy
- cystic fibrosis transmembrane conductance regulator (CFTR)
- gene targeting
- transmission electron microscopy (TEM)
Homologous replacement is a technology that can be used to modify specific genes within chromosomal DNA [1–6]. The potential of this type of strategy has obvious implications for maintaining genomic integrity and cell-specific expression. The direct conversion of mutant genomic sequences to a wild-type genotype, restoring the normal phenotype, has clear advantages over therapeutic cDNA. By preserving the integrity of the targeted gene, the relationship between the coding sequences and regulatory elements remains intact. Consequently, cell-specific expression is not altered. Small fragment homologous replacement (SFHR) involves the introduction of small fragments (~500-bp) of DNA into cells. After entering the cells, the fragment pairs with its genomic homologue and replaces the endogenous sequence with the exogenous fragment through an, as yet, undefined mechanism [1, 2, 6].
SFHR has already been successfully used to correct ΔF508 mutation in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene [1, 2, 7–10]. The ΔF508 is the most common mutation associated with CF [11, 12] and demonstration of its correction has significant therapeutic implications. The studies showed that SFHR-mediated replacement of mutant or wild-type genomic sequences after the introduction of small DNA fragment (491/488 nt) into cultured epithelial cells [7, 10]. In some studies, the fragment, also carried a silent mutation that introduced a unique XhoI restriction site that could be used as a secondary marker of SFHR-mediated correction [7, 8].
Recent in vivo studies have also indicated that SFHR could be used to modify endogenous mouse CFTR in the lung and in the intestine . Not only was it possible to demonstrate SFHR-mediated modification of the DNA, but there was also a clear indication that the cells expressing CFTR were modified . However, there has been no detailed SFHR optimization analysis as it relates to the behaviour of the DNA during and after SFHR uptake, the intracellular distribution of the DNA, and long-term stability of SFHR using non-viral vehicles. In this study, different parameters that influence SFHR in human epithelial cells were evaluated to determine whether SFHR could be an effective strategy for gene therapy. These include the type of transfected cells, DNA fragment to lipid ratio (+/-, respectively) and the time of harvest after initiation of transfection (incubation time). Different DNA transfection conditions were evaluated with respect to their ability to modulate SFHR-mediated correction.
SFHR-mediated replacement at the appropriate genomic locus and expression of the exogenous sequences was assayed using polymerase chain reaction (PCR) amplification, restriction fragment length polymorphic (RFLP) analysis and DNA sequencing. The intracellular fate of transfected gold-labelled DNA fragments was monitored by transmission electron microscopy (TEM). The results presented here provide insight into the mechanisms underlying SFHR-mediated correction of the most common CF mutation, the ΔF508.
Studies were carried out in CF tracheobronchial cells transformed with an origin of replication defective simian virus 40 (SV40) containing plasmid (pSVori-) [13–15]. The cell line, CFBE41o-, is homozygous for the ΔF508 mutation (ΔF508/ΔF508). A wild-type airway epithelial cell line 16HBE14o-, also transformed with the pSVori- plasmid was used as representative of the normal cells [14–16]. Cells were grown in Eagle's Minimal Essential Medium (MEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics under humidified conditions at 37°C in 5% CO2. Stock cultures were grown in T75 flasks coated with an extracellular matrix of collagen/fibronectin/bovine serum albumin and subculture by trypsinization as described previously .
Synthesis of DNA fragments
DNA fragments, 491-bp and 488-bp, that comprised exon 10 as well as the 3' and 5' flanking intron regions of the wild-type (wt) and mutant (ΔF508) CFTR gene respectively, were generated by PCR as previously described [7, 8, 10]. Fragments were column purified (Qiagen) and ethanol precipitated for subsequent use.
Preparation of lipid/fragment complexes
DNA-cationic lipid complexes were generated using the GENEPORTER (Gene Therapy Systems, San Diego, USA) liposome. The complexes were made at different charge ratios (+/-), by increasing the concentration of the double stranded DNA fragments and mixing with a constant quantity of LIPID (22.5 μl) according to manufacturer's specifications. The mixture was then incubated at room temperature for 45 min and diluted to a final volume of 2 ml with serum-free MEM. DNA without lipid was used as the control in all experiments.
Approximately 2.5 × 106 cells were seeded in T75 flask 24 h before treatment. Cells were incubated with lipoplexes for 5 h in serum free medium at 37°C. After the initial 5 h incubation, cell cultures were supplemented with medium containing a final 10% FBS concentration. Cells were harvested by trypsinization following removal of the culture medium and washing twice with cold Phosphate Buffered Saline (PBS).
PCR primers for SFHR DNA and RNA analysis
Total RNA was extracted by using RNeasy Mini kit (Qiagen, Germany). Reverse Transcriptase PCR (RT-PCR) amplification of total RNA was carried out using Superscipt™ II RNAse H- Reverse Transcriptase (Gibco BRL Life Technologies, Gaithersburg, USA) to generate first strand cDNA. The cDNA was initially amplified with primers external from the homology region (CF17/CF22) and then with primers (CF17/ΔF2) (Fig. 1B). The PCR product from this secondary amplification was extracted from the agarose gel as above and subjected to a final round of PCR amplification with primers (ΔF1/ΔF2). The amplicons were sized and analysed by densitometric analysis. Results are presented as the standard error of the mean. Oligonucleotide sequences are reported in Table I.
Transmission electron microscopy analysis (TEM) of gold-labelled DNA fragments
DNA fragments were gold-labelled with photoactive biotin (Pierce, Illinois, USA), and Auroprobe EM streptavidin G10 (Amersham, United Kingdom), as previously described . The CFBE41o- and 16HBE14o- cells were transfected with different amounts of labelled DNA/ lipid complex at varying charge ratios and analyzed at different times of transfection. Gold-labelled fragments (not complexed with lipid) were also transfected as controls. Cells were fixed for 1 hour at 4°C with 2.5% glutheraldheyde in 0.1 M Millonig's phosphate buffer (MPB) containing 2% sucrose. Samples were then post-fixed for 1 hour at 4°C with 1% OsO4 in MPB, dehydrated in ascending ethanol concentrations and embedded in Spurr epoxy resin (Agar Scientific LTD, Stanted, Essex, UK). Ultrathin sections were stained with uranyl acetate and lead citrate and observed under a Philips CM12 transmission electron microscope (Philips, Philips Electronics, NV).
Correction efficiency as function of lipid to DNA charge ratio (+/-): DNA analysis
Correction efficiency as function of lipid to DNA charge ratio (+/-): RNA analysis
Similar results were obtained for the 16HBE14o- cells transfected with the ΔF508 DNA fragment (Fig. 4C). Transcription of the ΔF508 mutant allele was only detectable at a lipid/DNA ratio of 2.2+/1- (Fig. 4C/D), corresponding to the maximum correction efficiency observable in genomic DNA (Fig. 3A/B).
Analysis of targeted replacement at different times after transfection with small DNA fragments
TEM analysis of lipoplex-cell interactions
The complexes appeared as structures around gold-labelled DNA (Fig. 6A). Some endosomes containing the complexes were near the cell surface suggesting that these were early endosomes (Fig. 6C). With an increase in the time of exposure to the transfection complexes, the endosomes appeared to move towards the perinuclear region. Late endosomes fused together to generate large membrane-bound vesicles containing aggregates of labelled complexes (Fig 7A,7B,7C). As shown in Fig. 7D,7E,7F,7G the DNA lipid complexes seemed to destabilize both endosomes and large membrane-bound vesicles. It should be noted that the destabilization site along the progression of the endosome to large vesicle seemed to be preferentially near the Golgi apparatus and the vesicular compartment of endoplasmic reticulum (Fig 7F,7G). These observations suggest that the DNA-liposomes complexes might be released into the cytoplasm by destabilizing either the endosome and large vesicle membrane and that the endoplasmic reticulum may be involved in the transport of free DNA towards the nucleus. Occasionally, gold labelled electron-dense material, apparently not bound to liposome structures, was observed near the ER and near the nuclear pores (data not shown). Free gold labelling was never observed in the nucleus. This may be due to the fact that, because of the size of the DNA fragments, not all the DNA was gold labeled. Consequently, our inability to observe free gold labeled DNA in the nucleus might reflect that very little DNA (gold labeled and unlabeled) escaped from the endosome and that the sensitivity of electron microscopy is not high enough to detect it. Alternatively, it is possible that, during the delivery of the DNA fragments from the complexes, some of the gold labelling was removed. At 96 hrs after the start of transfection, very large vesicles filled with gold-labelled complexes were observed (Fig 8A,8B,8C). Furthermore, large membranous bodies showing a regular lamellar pattern, similar to those described previously , were frequently observed (Fig 8D,8E). Of note is that the multilamellar packed structure of complexes that was still visible in the large cytoplasmic vesicles (Fig 8C), whereas in the large membranous bodies and apparent lysosomes the liposome complexes were not distinguishable (Fig 8E,8F). One possible explanation for this observation is that continued cellular exposure to the liposomes/DNA complexes results in their accumulation in large cytoplasmic vesicles. When the complexes in these vesicles exceed a critical concentration, the vesicles could neither fuse with lysosomes (Fig. 8C) and result in degradation of the complexes inside the large membranous bodies.
TEM analysis of cells treated with lipid/ DNA ratios that showed no SFHR-mediated modification showed labelled complexes adhering to the cytoplasmic membrane of a small number of cells (Fig. 9A). These complexes were never observed inside endosomes. Furthermore, in some cases the adherent complexes seemed to destabilize, the cell membrane (arrows in Fig. 9B). Both observations suggest that these lipid/DNA complexes penetrated the cell by a fusion mechanism. At these charge ratios, gold labelling was observed almost exclusively around and inside lysosomes (Fig. 9C,9D), and labelled complexes were never observed in late endosomes or large vesicles. These observations suggest that when lipid/DNA complexes enter the cell via a fusion mechanism, they are immediately digested by lysosomes. Thus, the entry of lipid/DNA complexes via an endocytic mechanism seems to be a requirement for the release of the DNA from the lipoplexes and transport into the nucleus. Controls were monitored in which labelled fragments, not complexed with lipid, were transfected for testing labelling toxicity. No fragments were seen inside cells (data not shown).
SFHR-mediated gene targeting has been used to correct a specific CFTR mutation, in the 3-bp ΔF508 deletion [7, 10]. Recently, this strategy was successfully employed to correct a nonsense mutation in the dystrophin (dys) locus of the mdx mouse both in vitro and in vivo. Previous studies have also shown that DNA fragments can be delivered to the lung by lipid vehicles. In this study, SFHR-mediated correction was detected up to seven days at mRNA level within lung and lower airways, suggesting its therapeutic potential within this organ .
These previous studies results suggest that SFHR has therapeutic potential for treatment of inherited disorders. However, to enhance this therapeutic potential, transfection conditions need to be optimized. This can, in part, be achieved by analysis of the cellular and molecular mechanisms that underlie transport of the therapeutic fragments to the nucleus. One of the necessary conditions to achieve therapeutically relevant SFHR-repair efficiencies is a careful optimization of delivery methodologies to overcome both extracellular and intracellular barriers that preclude the nuclear localization of the small fragments.
In fact, a major hurdle of gene therapy is the limited nuclear uptake of intact therapeutic DNA that inhibits its full performance .
The lipid/DNA ratio appears to be an important factor influencing the success of transfection [18, 23, 24]. The results of the studies presented here indicate that the lipid/DNA charge ratios for optimal SFHR-mediated modification are cell line dependent. A molar charge ratio of 2.2 (+)/1(-) and 6 (+)/1(-) for the wild-type (16HBE14o-) and the mutant (CFBE41o-) cell lines, respectively, was found to be optimal for SFHR when assessed by PCR. When the amount of lipid was held constant and the amount of DNA was increased, a more negatively charged lipid/DNA complex was formed. While increasing the amount of DNA in the lipoplexes, SFHR-mediated modification was observed to progressively decrease until it was undetectable (up to 30 μg of fragment). These findings indicate that the amount of DNA is not rate limiting in itself, but rather that the reduction in positive charge caused by an increase in DNA within the lipoplexes, impacts SFHR-mediated modification. This effect on SFHR was clearly cell line dependent and appears to be associated with the transport of the DNA to the nucleus. Alternatively, it can not be ruled out that the increased amount of DNA in negatively charge lipid/DNA complexes might competitively inhibit the enzymatic processes that leads to DNA uptake and/or SFHR. If the enzymatic pathways are saturated with DNA fragments they might not be as effective at mediating exchange. This will require further analysis in a future study.
Knowledge of the internalization mechanism and intracellular fate of lipoplexes is a prerequisite for the further development of efficient SFHR-based gene repair protocols. TEM analysis demonstrated that the lipoplexes enter cells via different mechanisms that depend on the lipid/DNA charge ratio. At a more negative charge ratio, lipoplexes enter into cells via a fusion pathway. Complexes that enter the cell via fusion with the plasma membrane appear not to enter the nucleus to mediate SFHR as is implied by the apparent lack of correction detected by molecular analysis. These results are consistent with previous work investigating the role of helper lipid in the assembly  and destabilization  of lipoplexes, and in the finding that lipid can inhibit SFHR-mediated modification of mutant plasmids after transient transfection .
The TEM analysis also demonstrated that lipoplexes with the appropriate charge could be taken up in endosomes within 5 h after initiation of transfection and become associated with the nucleus within 72 h. This endocytic uptake mechanism for the lipoplex appears to be distinct from that involving fusion with the plasma membrane, but also dependent on the lipoplex charge. As the lipoplex molar charge ratio becomes more positively charged, the lipoplexes appear to enter the cells via an endocytic pathway. It is this pathway that appears to be more effective at transferring DNA to the nucleus and mediating SFHR. Therefore, strategies that enhance endosome disruption might further improve delivery to the nucleus and thus potentiate SFHR-mediated modification. These include incorporation of synthetic virus-derived "fusogen" into the lipid complex [25, 26], the introduction of membrane destabilizing peptides into DNA/poly-lysine conjugates , transfection in the presence of inactivated adenovirus [28, 29] as well as treatment of the cells with agents that enhance endosome lysis such as chloroquine and glycerol [30–32].
SFHR-mediated DNA modification was detected within the population of transfected cells for at least 120 hours post-transfection. Analysis of the transfected CFBE41o- cells showed the 3-bp insertion at 11 days post-transfection. However, at 30 days, the insertion was no longer apparent. Recent studies in which the mixed population of transfected cells was sorted into isogenic cell lines have indicated that subpopulations of corrected cells exist within the larger population, albeit at a frequency that is detectable by allele-specific PCR . Thus, it does appear that SFHR-mediated modification of CFBE41o- cells is stable over time, but the proportion of corrected cell is reduced, leading to dilution of the signal because of the passing of time.
These studies demonstrate that the efficacy of lipid assisted SFHR-mediated modification appears to be cell line-dependent. Different charge ratios were optimal for SFHR-mediated targeting when comparing CFBE41o- cells to 16HBE14o- cells. This suggests that, as yet undefined, intracellular factors influence lipid-facilitated SFHR-mediated modification. The data are also consistent with previous observations that the efficiency of cationic lipid-mediated transfection varies with different cell types [18, 34, 35]. This issue will be particularly relevant to the selection of the delivery vehicles for SFHR in vitro and in vivo[9, 22].
While recent studies demonstrated that SFHR delivery can be achieved in vivo in the mouse lung  and muscle , there are still questions that need to be answered before SFHR can be applied therapeutically. Although it is difficult to extrapolate conditions and optimal delivery vehicle formulations from in vitro experiments to in vivo, these studies on human airway epithelial cell lines provide insights into therapeutic application of SFHR in human airways. In the context of a reliable assay system these cell systems, can be useful for elucidating those conditions that will optimize SFHR in the airways [18, 24].
This work was supported by Ministero della Sanità and Regione Lazio Fondo Sanitario Nazionale per la Prevenzione e la Cura della Fibrosi Cistica (Legge 23 dicembre 1993, n.548), NIDDK 46002, 47766, CFF, CFRI and PACFI.
- Gruenert DC: Gene correction with small DNA fragments. Curr Res Molec Ther. 1998, 1: 607-613.Google Scholar
- Gruenert DC: Opportunities and challenges in targeting genes for therapy. Gene Ther. 1999, 6: 1347-1348. 10.1038/sj.gt.3301011.View ArticlePubMedGoogle Scholar
- Kmiec EB: Targeted gene repair. Gene Ther. 1999, 6: 1-3. 10.1038/sj.gt.3300789.View ArticlePubMedGoogle Scholar
- Lai LW, Lien YH: Homologous recombination based gene therapy. Exp Nephr. 1999, 7: 11-14. 10.1159/000020578.View ArticleGoogle Scholar
- Woolf TM: Therapeutic repair of mutated nucleic acid sequences. Nat Biotechnol. 1998, 16: 341-344.View ArticlePubMedGoogle Scholar
- Yanez RJ, Porter ACG: Therapeutic gene targeting. Gene Ther. 1998, 5: 149-159. 10.1038/sj.gt.3300601.View ArticlePubMedGoogle Scholar
- Goncz KK, Kunzelmann K, Xu Z, Gruenert DC: Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet. 1998, 7: 1913-1919. 10.1093/hmg/7.12.1913.View ArticlePubMedGoogle Scholar
- Goncz KK, Gruenert DC: Site-directed alteration of DNA by small fragment homologous replacement (SFHR). In: Gene Targeting Vector Protocols. Edited by: Kmiec EB, Totowa NJ. 1998, Humana Press, 85-99.Google Scholar
- Goncz KK, Colosimo A, Dallapiccola B, Gagne L, Hong K, Novelli G, D Papahadjopoulos, Sawa T, Schreier H, Wiener-Kronish J, et al: Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. Gene Ther. 2001, 8: 961-965. 10.1038/sj.gt.3301476.View ArticlePubMedGoogle Scholar
- Kunzelmann K, Legendre JK, Knoell D, Escobar LC, Xu Z, Gruenert DC: Gene Targeting of CFTR DNA in CF epithelial cells. Gene Ther. 1996, 3: 859-867.PubMedGoogle Scholar
- Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis. Science. 1989, 245: 1073-1080.View ArticlePubMedGoogle Scholar
- Tsui LC: The spectrum of cystic fibrosis mutations. Trends in Genet. 1992, 8: 392-398.View ArticleGoogle Scholar
- Cozens AL, Yezzi MJ, Chin L, Simon EM, Finkbeiner WE, Wagner JA, Gruenert DC: Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. Proc Natl Acad Sci USA. 1992, 89: 5171-5175.View ArticlePubMedPubMed CentralGoogle Scholar
- Gruenert DC, Basbaum CB, Welsh MJ, Li M, Finkbeiner WE, Nadel JA: Characterisation of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc Natl Acad Sci USA. 1988, 85: 5951-5955.View ArticlePubMedPubMed CentralGoogle Scholar
- Gruenert DC, Finkbeiner WE, Widdicombe JH: Culture and transformation of human airway epithelial cells. Am J Physiol. 1995, 268: L347-360.PubMedGoogle Scholar
- Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, Finkbeiner WE, Widdicombe JH, Gruenert DC: CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1994, 10: 38-47.View ArticlePubMedGoogle Scholar
- Gruenert DC, Basbaum CB, Widdicombe JH: Long-term culture of normal and cystic fibrosis epithelial cells grown under serum-free conditions. In Vitro Cell Dev Biol. 1990, 26: 411-418.View ArticlePubMedGoogle Scholar
- Colosimo A, Goncz KK, Holmes AR, Kunzelmann K, Novelli G, Malone RW, Benneth MJ, Gruenert DC: Transfer and expression of foreign genes in mammalian cells. Biotechniques. 2000, 29: 314-318.PubMedGoogle Scholar
- Densomore CL, Giddings TH, Waldrep JC, Kinsey BM, Knight V: Gene transfer by guanidinium-cholesterol-dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J Gene Med. 1999, 1: 251-264. 10.1002/(SICI)1521-2254(199907/08)1:4<251::AID-JGM43>3.3.CO;2-Q.View ArticleGoogle Scholar
- Felgner PL: Nonviral strategies for gene therapy. Sci Am. 1997, 276: 102-106.View ArticlePubMedGoogle Scholar
- Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic liposome. J Biol Chem. 1995, 270: 18997-19007. 10.1074/jbc.270.32.18997.View ArticlePubMedGoogle Scholar
- Kapsa R, Quigley A, Lynch GS, Steeper K, Kornberg AJ, Gregorevic P, Austin L, Byrne E: In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther. 2001, 12: 29-642. 10.1089/104303401300057324.View ArticleGoogle Scholar
- Colosimo A, Sangiuolo F, Di Sario S, Amicucci P, Serafino AL, Novelli A, Sabati M, Castro M, Lucidi V, Mossa G, Dalla piccola B, Novelli G: Current status of cationic liposome-mediated gene therapy in cystic fibrosis. Acta Pharm. 1998, 4: 221-227.Google Scholar
- Colosimo A, Goncz KK, Novelli G, Dallapiccola B, Gruenert DC: Targeted correction of a defective selectable marker gene in human epithelial cells by small DNA fragments. Mol Ther. 2001, 3: 178-185. 10.1006/mthe.2000.0242.View ArticlePubMedGoogle Scholar
- Scheule RK, Bagley RG, Erickson AL, Wang KX, Fang SL, Vaccaro C, O'Riordan CR, Cheng SH, Smith AE: Delivery of purified, functional CFTR to epithelial cells in vitro using influenza hemagglutinin. Am J Respir Cell Mol Biol. 1995, 13: 330-343.View ArticlePubMedGoogle Scholar
- Schreier H, Ausborn M, Gunther S, Weissig V, Chander R: (Patho)physiologic pathways to drug targeting: artificial viral envelopes. J Mol Recognit. 1995, 8: 59-62.View ArticlePubMedGoogle Scholar
- Schwarzenberg P, Huang W, Oliver P, Osidipe T, Theodossiou C, Kolls JK: Poly-L-Lisine based molecular conjugate vectors: a high efficiency gene transfer system for human progenitor and leukemia cells. Am J Med Sci. 2001, 321: 129-136. 10.1097/00000441-200102000-00004.View ArticleGoogle Scholar
- Kafri T: Lentivirus vectors: difficulties and hopes before clinical trials. Curr Opin Mol Ther. 2001, 3: 316-26.PubMedGoogle Scholar
- Evans JT, Cravens P, Gatlin J, Kelly PF, Lipsky PE, Garcia JV: Pre-clinical evaluation of an in vitro selection protocol for the enrichment of transduced CD34(+) cell-derived human dendritic cells. Gene Ther. 2001, 8: 1427-35. 10.1038/sj.gt.3301530.View ArticlePubMedGoogle Scholar
- Remy-Kristensen A, Clamme JP, Vuilleumier C, Kuhry JG, Mely Y: Role of endocytosis in the transfection of L929 fibroblasts by polyethylenimine/DNA complexes. Biochim Biophys Acta. 2001, 1514: 21-32.View ArticlePubMedGoogle Scholar
- Ma H, Diamnond SL: Nonviral gene therapy and its delivery systems. Curr Pharm Biotechnol. 2001, 2: 1-17.View ArticlePubMedGoogle Scholar
- Nishikawa M, Huang L: Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther. 2001, 12: 861-70. 10.1089/104303401750195836.View ArticlePubMedGoogle Scholar
- Bruscia E, Sangiuolo F, Goncz KK, Novelli G, Gruenert DC: Isolation of CF cell lines corrected at ΔF508-CFTRlocus by SFHR-mediated targeting. Gene Ther. 2002, Google Scholar
- Caplen NJ, Kinrade E, Sorgi F, Gao X, Gruenert DC, Geddes D, Coutelle C, Huang L, Alton EW, Williamson R: In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Ther. 1995, 2: 603-613.PubMedGoogle Scholar
- Gao XA, Huang LA: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun. 1991, 179: 280-285.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/3/8/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.